GlassScriptPhysician profile
Benjamin David Demoss
NPI 1356668081
$17,486.67
in general payments reported to CMS, 2019-2025
34 companies · $2,953 in 2025
The $2,953 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $299 · 2021: $6,038 · 2022: $5,326 · 2023: $1,648 · 2024: $1,032 · 2025: $2,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069 · Consulting Fee: $2,563 · Travel and Lodging: $1.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,069.09 |
| Consulting Fee | $2,562.50 |
| Travel and Lodging | $1.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14,108.58 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $595.22 | 2021-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $431.44 | 2019-2025 | Lifevest |
| Medtronic, INC. | $426.55 | 2024-2025 | Mc3 Nautilus(Tm) Ecmo Oxygenator, Penditure, Symplicity G3 |
| Merck Sharp & Dohme LLC | $299.74 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $276.36 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $254.54 | 2020-2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.11 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $147.03 | 2019-2025 | Wainua |
| Pfizer INC. | $127.87 | 2019-2025 | |
| Edwards Lifesciences Corporation | $71.06 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.48 | 2022-2024 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $39.38 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.00 | 2025 | Livtencity |
| Nuwellis, INC. | $31.53 | 2022-2025 | Aquadex Smartflow Console |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $28.77 | 2025 | Attruby |
| Procyrion, INC. | $28.57 | 2025 | Aortix System |
| Amgen INC. | $24.43 | 2020 | |
| Atricure, INC. | $22.07 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Actelion Pharmaceuticals US, INC. | $21.90 | 2024 | Opsumit, Uptravi |
| Daiichi Sankyo INC. | $21.65 | 2021 | |
| Phadia US INC. | $20.13 | 2022 | |
| Novo Nordisk INC | $19.89 | 2024 | Rybelsus, Ozempic |
| Kestra Medical Technology Services, INC. | $18.85 | 2023 | Assure Wcd |
| Haemonetics Corporation | $17.61 | 2024 | Teg6s Hemostasis System |
| Astellas Pharma US INC | $17.49 | 2025 | Cresemba |
| Akcea Therapeutics, INC. | $16.57 | 2019 | |
| Argon Medical Devices, INC. | $16.36 | 2025 | Clot Management |
| Kiniksa Pharmaceuticals, LTD. | $16.19 | 2023 | Arcalyst |
| Heartflow, INC. | $15.48 | 2025 | |
| Boston Scientific Corporation | $14.73 | 2022 | |
| Abiomed | $14.44 | 2024 | Impella |
| Impulse Dynamics (USA) INC. | $13.97 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Demoss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.